Nimotuzumab inhibits epithelial –mesenchymal transition in prostate cancer by targeting the Akt/YB‐1/AR axis

In this study, we presented our novel findings that by targeting the Akt/YB‐1/AR axis, nimotuzumab significantly inhibited EMT of PC cells. Considering that EMT is a critical mechanism contributing to the metastatic spread of cancer cells, nimotuz umab may become a promising therapy for alleviating the malignant progression of PC. © 2019 IUBMB Life, 1–14, 2019
Source: IUBMB Life - Category: Research Authors: Tags: Research Communication Source Type: research